Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024).
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
Seeking Alpha / 12 hours ago 1 Views
Comments